Dante Pieramici, MD

Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.

Dante Pieramici, MD, on how a sustained-release TKI dosed every six months could cut clinic volume, ease treatment burden, and protect patients who otherwise disappear from care.

Dante Pieramici, MD, discusses EYP-1901, a sustained-delivery tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 JAK/STAT signaling, in the phase 3 COMO and CAPRI diabetic macular edema trials.

Dante Pieramici, MD, breaks down the phase 3 COMO and CAPRI trials of EYP-1901 (Duravyu), an insert designed to ease treatment burden in diabetic macular edema.